{"id":"W1988024888","doi":"10.1517/13543784.2013.822485","title":"Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia","year":2013,"lang":"en","type":"review","venue":"Expert Opinion on Investigational Drugs","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"PCSK9; Ezetimibe; Alirocumab; Proprotein convertase; Evolocumab; Pharmacology; Tolerability; Kexin; Niacin; Medicine; Statin; Familial hypercholesterolemia; Dyslipidemia; Adverse effect; Internal medicine; Cholesterol; Endocrinology; Apolipoprotein B; Lipoprotein; LDL receptor; Disease; Apolipoprotein A1","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004916501,0.000727342,0.001181371,0.001152944,0.0001728375,0.0007287762,0.0008052514,0.0009384191,0.008550635],"category_scores_gemma":[0.0005521725,0.0001777016,0.0006839015,0.001375806,0.0002455567,0.0007386644,0.0004461722,0.001360743,0.005135356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004138598,"about_ca_system_score_gemma":0.0007951637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005079214,"about_ca_topic_score_gemma":0.001337137,"domain_scores_codex":[0.9997925,0.00003520291,0.00002490594,0.00002960419,0.00009531181,0.00002248845],"domain_scores_gemma":[0.9997539,0.00007165703,0.00006768118,0.00000617365,0.00007677815,0.00002385345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009306829,0.00006285777,0.00007278401,0.01410646,0.00009323397,0.00009502045,0.00001962549,0.000120697,0.001320713,0.0009289528,0.04049582,0.9425908],"study_design_scores_gemma":[0.00009397381,0.0001536856,0.0007105026,0.00669535,0.0002574137,0.001132173,0.00003111457,0.00008741672,0.0005545318,0.001010182,0.9892587,0.00001492767],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001748447,0.9958286,0.0002231066,0.0006099275,0.0003188718,0.00002350459,0.00005751371,0.00001743158,0.002746232],"genre_scores_gemma":[0.0008700512,0.9962999,0.0003122567,0.0005500781,0.0002649575,0.00002053175,0.00009907776,0.000002919167,0.001580241],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008550635,"threshold_uncertainty_score":0.02860475,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09729688680475103,"score_gpt":0.4063385413648205,"score_spread":0.3090416545600695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}